BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 19433373)

  • 1. [Angiogenesis: a new therapeutic target of thoracic and laryngopharyngeal carcinoma].
    Taillade L; Alexandre I; Billemont B; Meric JB; Sultan-Amar V; Rixe O
    Bull Cancer; 2009; 96 Suppl 1():S45-55. PubMed ID: 19433373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Langer CJ; Natale RB
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Angiogenesis and lung cancer].
    Pérol M; Arpin D
    Bull Cancer; 2007 Jul; 94 Spec No():S220-31. PubMed ID: 17846008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiogenesis inhibitors in the treatment of lung cancer.
    Sun S; Schiller JH
    Crit Rev Oncol Hematol; 2007 May; 62(2):93-104. PubMed ID: 17306557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
    Pradeep CR; Sunila ES; Kuttan G
    Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of angiogenesis in the treatment of non-small cell lung cancer.
    Keedy VL; Sandler AB
    Cancer Sci; 2007 Dec; 98(12):1825-30. PubMed ID: 17892508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors.
    Tandle A; Libutti SK
    Clin Adv Hematol Oncol; 2003 Jan; 1(1):41-8. PubMed ID: 16227959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New antiangiogenetic agents and non-small cell lung cancer.
    Gridelli C; Rossi A; Maione P
    Crit Rev Oncol Hematol; 2006 Oct; 60(1):76-86. PubMed ID: 16843002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiangiogenic therapy in nonsmall cell lung cancer.
    Gutierrez M; Giaccone G
    Curr Opin Oncol; 2008 Mar; 20(2):176-82. PubMed ID: 18300767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multitargeted inhibitors in lung cancer: new clinical data.
    Bar J; Herbst RS; Onn A
    Clin Lung Cancer; 2008; 9 Suppl 3():S92-9. PubMed ID: 19419930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.
    Hicklin DJ; Ellis LM
    J Clin Oncol; 2005 Feb; 23(5):1011-27. PubMed ID: 15585754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
    Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
    Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiogenesis inhibitors: a rational strategy for radiosensitization in the treatment of non-small-cell lung cancer?
    Raben D; Helfrich B
    Clin Lung Cancer; 2004 Jul; 6(1):48-57. PubMed ID: 15310417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiogenesis inhibition in solid tumors.
    Rosen LS
    Cancer J; 2001; 7 Suppl 3():S120-8. PubMed ID: 11779082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting angiogenesis in lung cancer.
    Sandler AB
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S16-22. PubMed ID: 16459175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
    Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
    Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Are antiangiogenic antibodies universal for solid tumor?].
    Ray-Coquard I; Bachelot T; Saba C; Confavreux C; Brantus JF; Rustam F; Ghesquière H; Sebban C; Biron P; Guastalla JP; Blay JY
    Bull Cancer; 2007 Jul; 94 Spec No():S191-6. PubMed ID: 17846004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.